Intuitive Surgical’s Overseas Growth Faces Pressure Despite Strong Q1 Results

Intuitive Surgical, the maker of the da Vinci robotic surgery system, delivered a strong first quarter, but investors are watching one important issue: weakness in some international markets. The company reported Q1 2026 revenue of $2.77 billion, up 23% year over year, while da Vinci procedures grew 16% and total procedures rose 17%.

China and Japan Remain the Main Concerns

The biggest pressure points are China and Japan. Management said China continues to face low tender activity, rising local competition, and pricing pressure. In Japan, procedure growth improved from the previous quarter but stayed below past levels because fewer systems were placed in 2025.

System placements show the split clearly. Intuitive placed 431 da Vinci systems globally in Q1 2026, but only 13 were placed in Japan and 4 in China. Outside the United States, total placements still rose to 205 from 163 a year earlier, helped by Europe, especially the United Kingdom.

Europe Helps Offset Asian Weakness

Europe was a bright spot. Intuitive reported 117 system placements in Europe, compared with 88 a year earlier. The U.K. played a major role, with 34 systems placed as the NHS closed out its budget year. This suggests that international demand is not weak everywhere, but rather uneven by region.

Why the Weakness May Be Temporary

Some of the pressure could be short term. In Japan, new reimbursement support is expected to begin in June 2026 for seven additional robotic procedures. Rectal resection also received premium reimbursement when performed robotically. These policy changes may help hospitals justify more robotic surgery use over time.

Intuitive also raised its full-year 2026 da Vinci procedure growth outlook to 13.5%-15.5%, up from 13%-15%. That shows management still sees strong global procedure demand despite weak spots in China and Japan.

Why the Risk Could Be Structural

Still, China may be a deeper challenge. Low tender volumes, domestic competition, and policy-driven pricing pressure could last longer than one or two quarters. Management said clarity on possible charge-code and reimbursement changes in China may not come until 2027.

This matters because Intuitive’s international opportunity is central to its long-term growth story. Outside-U.S. procedures now represent 38% of total da Vinci volume, up from 25% about a decade ago.

Core Business Still Looks Strong

Despite these concerns, Intuitive’s core business remains healthy. The company had 11,395 da Vinci systems installed worldwide as of March 31, 2026, including 6,477 in the United States, 2,257 in Europe, 2,049 in Asia, and 612 in the rest of the world.

Recurring revenue also gives the business stability. In Q1, recurring revenue reached $2.4 billion, making up 86% of total revenue. Instrument and accessory revenue increased 23% to $1.7 billion, while service revenue grew 19% to $434 million.

Investor Takeaway

Intuitive Surgical’s international weakness looks mixed. Japan’s pressure may ease as reimbursement improves and hospitals regain spending power. China, however, appears more complex because competition, pricing rules, and tender delays could remain a structural drag.

Even so, the company’s strong U.S. performance, European momentum, growing da Vinci 5 adoption, and high recurring revenue base suggest that Intuitive Surgical is not facing a broad demand problem. The main question is whether China and Japan can return to stronger growth before investors begin treating the weakness as a permanent risk.

#IntuitiveSurgical #ISRG #RoboticSurgery #StockMarketNews #SlimScan #GrowthStocks #CANSLIM